Evidence map›Paper›PMID 34884764›Full record

ReviewInternational journal of molecular sciences2021

The Effect of Organoselenium Compounds on Histone Deacetylase Inhibition and Their Potential for Cancer Therapy.

Theolan Adimulam, Thilona Arumugam, Ashmika Foolchand, Terisha Ghazi, Anil A Chuturgoon

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Theolan AdimulamDepartment of Medical Biochemistry, School of Laboratory Medicine and Medical Science, College of Health Sciences, Howard College Campus, University of KwaZulu-Natal, Durban 4041, South Africa.ORCID 0000-0002-7304-064X
Thilona ArumugamDepartment of Medical Biochemistry, School of Laboratory Medicine and Medical Science, College of Health Sciences, Howard College Campus, University of KwaZulu-Natal, Durban 4041, South Africa.
Ashmika FoolchandDepartment of Medical Biochemistry, School of Laboratory Medicine and Medical Science, College of Health Sciences, Howard College Campus, University of KwaZulu-Natal, Durban 4041, South Africa.ORCID 0000-0001-7721-5489
Terisha GhaziDepartment of Medical Biochemistry, School of Laboratory Medicine and Medical Science, College of Health Sciences, Howard College Campus, University of KwaZulu-Natal, Durban 4041, South Africa.ORCID 0000-0002-0179-213X
Anil A ChuturgoonDepartment of Medical Biochemistry, School of Laboratory Medicine and Medical Science, College of Health Sciences, Howard College Campus, University of KwaZulu-Natal, Durban 4041, South Africa.ORCID 0000-0003-4649-4133
University of KwaZulu-Natal · ZA

Funding

National Research Foundation 120820
6 · The paper itself

Abstract

Genetic and epigenetic changes alter gene expression, contributing to cancer. Epigenetic changes in cancer arise from alterations in DNA and histone modifications that lead to tumour suppressor gene silencing and the activation of oncogenes. The acetylation status of histones and non-histone proteins are determined by the histone deacetylases and histone acetyltransferases that control gene transcription. Organoselenium compounds have become promising contenders in cancer therapeutics. Apart from their anti-oxidative effects, several natural and synthetic organoselenium compounds and metabolites act as histone deacetylase inhibitors, which influence the acetylation status of histones and non-histone proteins, altering gene transcription. This review aims to summarise the effect of natural and synthetic organoselenium compounds on histone and non-histone protein acetylation/deacetylation in cancer therapy.

Indexed as

AcetylationDrug Delivery SystemsEpigenesis, GeneticHistone CodeHistone Deacetylase InhibitorsHistone DeacetylasesHistonesHumansMolecular Targeted TherapyNanoparticlesNeoplasmsOrganoselenium CompoundsProtein Processing, Post-TranslationalHistone Deacetylase InhibitorsHistone DeacetylasesHistonesOrganoselenium Compoundscancerhistone deacetylationmethylselenocysteineorganoselenium compoundsselenocysteineselenomethionine

Identifiers

PMID34884764
PMCPMC8657714
OpenAlexW3216253667

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.